SKSpencer Keene

Spencer Keene

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Spencer Keene has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Using population-wide electronic health records for timely contemporary assessment of cardiovascular disease risk prediction model performance: COVID-19 impact on the SCORE2 models

    by Carmen Petitjean, Spencer J Keene, Thomas Bolton, Alexia Sampri, Genevieve Cezard, Samantha Ip, Fionna Chalmers, Anna J Stevenson, Stelios Boulitsakis Logothetis, Spiros Denaxas, et al.

    Aims: Risk estimation is key for the primary prevention of cardiovascular diseases (CVD). The European Society of Cardiology recommends SCORE2, SCORE2-OP (Older Persons), and SCORE2-Diabetes [collectively, the SCORE2 family-of-models (FOMs)] for 10-year CVD risk estimation. As the COVID-19 pandemic was associated with higher CVD incidences, we externally validated the SCORE2-FOMs using contemporary nationwide data and assessed the need for adaptation. Methods: Using population-wide electronic health records (EHRs) for England, we defined a cohort of 26.5 million individuals aged 40–89 years without prior CVD on 1 January 2022 followed up until 31 December 2023. We calculated annual incidence rates of CVD events and non-CVD mortality by sex and 1-year age groups to estimate expected 10-year, competing risk adjusted, CVD risk using a life table approach. We assessed SCORE2-FOM calibration and discrimination, overall and by subgroups. Results: Within 2 years of follow-up, 239 815 incident CVD events occurred. For SCORE2, SCORE2-Diabetes, and SCORE2-OP, the C-index values were 0.75 (95% CI: 0.75–0.76), 0.71 (0.71–0.71), and 0.65 (0.65–0.65), respectively. SCORE2-FOMs overpredicted CVD risks by 3%–4% in males and by 8%–14% in females, with calibration variations by English region and ethnic group. Elevated CVD risk associated with a recent COVID-19 hospitalization led SCORE2 to underestimate risks by 2% in affected males aged 40–69 years. Conclusion: The SCORE2-FOMs demonstrated good calibration and discrimination, suggesting that no adaptation is needed in response to the COVID-19 pandemic. Short-term EHRs provide a valuable resource for timely contemporary risk model validation and, if necessary, for adaptation according to shifts in CVD trends.

  • Open Access

    Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model

    by Tessa H Reitsma, Carl-Emil Lim, Mari N Gynnild, Stephen Kaptoge, Laura Lõo, Joris Holtrop, Łukasz Kuźma, Lisa Pennells, Nathalie Conrad, Peter Ueda, et al.

    Background and Aims: Patients with established atherosclerotic cardiovascular disease (ASCVD) are at high risk of developing heart failure (HF). However, incident HF is not part of the risk assessment of current guideline-recommended models. The aim of this study was to develop and externally validate the SMART2-HF model for prediction of incident HF in patients with ASCVD. Methods: SMART2-HF was developed in 7698 individuals with established ASCVD (coronary, cerebrovascular, or peripheral artery disease, or abdominal aortic aneurysm) but without prior HF from the UCC-SMART cohort. Cox proportional hazards models including sex-predictor interactions and with age as the time scale were derived to estimate the 10-year and lifetime risk of incident HF (hospitalization for HF or HF-related death), accounting for competing non-HF mortality. Predictors, limited to routinely available clinical characteristics, were aligned with the SMART2 risk model for recurrent cardiovascular (CV) risk in the same population. External validation was performed in 240 741 patients with ASCVD from six data sources: the Clinical Practice Research Datalink, the HUNT3 study, the SWEDEHEART Registry, the ASCVD-Particles cohort, the Estonian Biobank and the international REACH Registry. Results: During a median follow-up of 11.2 years (interquartile range 6.1–16.4 years), 1031 incident HF events (13%) occurred in the UCC-SMART cohort. In the external validation data sources, a total of 24 885 incident HF events (10%) occurred. The pooled C-statistic was .696 (95% confidence interval .674–.717), with consistent performance in subgroups by sex and type of ASCVD. Predicted risks matched observed incidence in external validation. Conclusions: The SMART2-HF model enables the prediction of incident HF in patients with ASCVD. Aligned with the guideline-recommended SMART2 model for recurrent CV risk, SMART2-HF can be used as a complementary tool in this population.


  • Open Access

    Risks of major arterial and venous thrombotic diseases after hospitalisation for influenza, pneumonia, and COVID-19: A population-wide cohort in 2.6 million people in Wales

    by Spencer Keene, Hoda Abbasizanjani, Fatemeh Torabi, Rochelle Knight, Venexia Walker, Elena Raffetti, Genevieve Cezard, Samantha Ip, Alexia Sampri, Thomas Bolton, et al.


  • Open Access

    Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England

    by Samantha Ip, Teri-Louise North, Fatemeh Torabi, Yangfan Li, Hoda Abbasizanjani, Ashley Akbari, Elsie Horne, Rachel Denholm, Spencer Keene, Spiros Denaxas, et al.

    The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in England between December 2020 and January 2022, our study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second and booster doses of brands and combinations of COVID-19 vaccines used during the UK vaccination program with the incidence before or without the corresponding vaccination. The incidence of common arterial thrombotic events (mainly acute myocardial infarction and ischaemic stroke) was generally lower after each vaccine dose, brand and combination. Similarly, the incidence of common venous thrombotic events, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination. There was a higher incidence of previously reported rare harms after vaccination: vaccine-induced thrombotic thrombocytopenia after first ChAdOx1 vaccination, and myocarditis and pericarditis after first, second and transiently after booster mRNA vaccination (BNT-162b2 and mRNA-1273). These findings support the wide uptake of future COVID-19 vaccination programs.


  • Top Cited Papers
    Open Access

    Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales

    by Rochelle Knight, Venexia Walker, Samantha Ip, Jennifer A. Cooper, Thomas Bolton, Spencer Keene, Rachel Denholm, Ashley Akbari, Hoda Abbasizanjani, Fatemeh Torabi, et al.

    Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a prothrombotic state, but long-term effects of COVID-19 on incidence of vascular diseases are unclear. Methods: We studied vascular diseases after COVID-19 diagnosis in population-wide anonymized linked English and Welsh electronic health records from January 1 to December 7, 2020. We estimated adjusted hazard ratios comparing the incidence of arterial thromboses and venous thromboembolic events (VTEs) after diagnosis of COVID-19 with the incidence in people without a COVID-19 diagnosis. We conducted subgroup analyses by COVID-19 severity, demographic characteristics, and previous history. Results: Among 48 million adults, 125 985 were hospitalized and 1 319 789 were not hospitalized within 28 days of COVID-19 diagnosis. In England, there were 260 279 first arterial thromboses and 59 421 first VTEs during 41.6 million person-years of follow-up. Adjusted hazard ratios for first arterial thrombosis after COVID-19 diagnosis compared with no COVID-19 diagnosis declined from 21.7 (95% CI, 21.0–22.4) in week 1 after COVID-19 diagnosis to 1.34 (95% CI, 1.21–1.48) during weeks 27 to 49. Adjusted hazard ratios for first VTE after COVID-19 diagnosis declined from 33.2 (95% CI, 31.3–35.2) in week 1 to 1.80 (95% CI, 1.50–2.17) during weeks 27 to 49. Adjusted hazard ratios were higher, for longer after diagnosis, after hospitalized versus nonhospitalized COVID-19, among Black or Asian versus White people, and among people without versus with a previous event. The estimated whole-population increases in risk of arterial thromboses and VTEs 49 weeks after COVID-19 diagnosis were 0.5% and 0.25%, respectively, corresponding to 7200 and 3500 additional events, respectively, after 1.4 million COVID-19 diagnoses. Conclusions: High relative incidence of vascular events soon after COVID-19 diagnosis declines more rapidly for arterial thromboses than VTEs. However, incidence remains elevated up to 49 weeks after COVID-19 diagnosis. These results support policies to prevent severe COVID-19 by means of COVID-19 vaccines, early review after discharge, risk factor control, and use of secondary preventive agents in high-risk patients.


  • Top Cited Papers
    Open Access

    Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England

    by William N. Whiteley, Samantha Ip, Jennifer A. Cooper, Thomas Bolton, Spencer Keene, Venexia Walker, Rachel Denholm, Ashley Akbari, Efosa Omigie, Sam Hollings, et al.

    Background: Thromboses in unusual locations after the Coronavirus Disease 2019 (COVID-19) vaccine ChAdOx1-S have been reported, although their frequency with vaccines of different types is uncertain at a population level. The aim of this study was to estimate the population-level risks of hospitalised thrombocytopenia and major arterial and venous thromboses after COVID-19 vaccination. Methods and findings: In this whole-population cohort study, we analysed linked electronic health records from adults living in England, from 8 December 2020 to 18 March 2021. We estimated incidence rates and hazard ratios (HRs) for major arterial, venous, and thrombocytopenic outcomes 1 to 28 and >28 days after first vaccination dose for ChAdOx1-S and BNT162b2 vaccines. Analyses were performed separately for ages 2, sex, ethnicity, and deprivation. We also prespecified adjustment for anticoagulant medication, combined oral contraceptive medication, hormone replacement therapy medication, history of pulmonary embolism or deep vein thrombosis, and history of coronavirus infection in analyses of venous thrombosis; and diabetes, hypertension, smoking, antiplatelet medication, blood pressure lowering medication, lipid lowering medication, anticoagulant medication, history of stroke, and history of myocardial infarction in analyses of arterial thromboses. We selected further covariates with backward selection. Of 46 million adults, 23 million (51%) were women; 39 million (84%) were 28 days post-ChAdOx1-S, 359 (338 to 382), ≤28 days post-BNT162b2-S, 241 (229 to 253); >28 days post-BNT162b2-S 277 (263 to 291). The crude incidence rates (per 100,000 person-years) of all arterial events were as follows: prevaccination, 546 (95% CI: 541 to 555); ≤28 days post-ChAdOx1-S, 1,211 (1,185 to 1,237); >28 days post-ChAdOx1-S, 1678 (1,630 to 1,726), ≤28 days post-BNT162b2-S, 1,242 (1,214 to 1,269); >28 days post-BNT162b2-S, 1,539 (1,507 to 1,572). Adjusted HRs (aHRs) 1 to 28 days after ChAdOx1-S, compared with unvaccinated rates, at ages <70 and ≥70 years, respectively, were 0.97 (95% CI: 0.90 to 1.05) and 0.58 (0.53 to 0.63) for venous thromboses, and 0.90 (0.86 to 0.95) and 0.76 (0.73 to 0.79) for arterial thromboses. Corresponding aHRs for BNT162b2 were 0.81 (0.74 to 0.88) and 0.57 (0.53 to 0.62) for venous thromboses, and 0.94 (0.90 to 0.99) and 0.72 (0.70 to 0.75) for arterial thromboses. aHRs for thrombotic events were higher at younger ages for venous thromboses after ChAdOx1-S, and for arterial thromboses after both vaccines. Rates of intracranial venous thrombosis (ICVT) and of thrombocytopenia in adults aged <70 years were higher 1 to 28 days after ChAdOx1-S (aHRs 2.27, 95% CI: 1.33 to 3.88 and 1.71, 1.35 to 2.16, respectively), but not after BNT162b2 (0.59, 0.24 to 1.45 and 1.00, 0.75 to 1.34) compared with unvaccinated. The corresponding absolute excess risks of ICVT 1 to 28 days after ChAdOx1-S were 0.9 to 3 per million, varying by age and sex. The main limitations of the study are as follows: (i) it relies on the accuracy of coded healthcare data to identify exposures, covariates, and outcomes; (ii) the use of primary reason for hospital admission to measure outcome, which improves the positive predictive value but may lead to an underestimation of incidence; and (iii) potential unmeasured confounding. Conclusions: In this study, we observed increases in rates of ICVT and thrombocytopenia after ChAdOx1-S vaccination in adults aged <70 years that were small compared with its effect in reducing COVID-19 morbidity and mortality, although more precise estimates for adults aged <40 years are needed. For people aged ≥70 years, rates of arterial or venous thrombotic events were generally lower after either vaccine compared with unvaccinated, suggesting that either vaccine is suitable in this age group.


  • Smoking and BMI in COPD and non-COPD patients

    by Spencer Keene, Annmariek Driessen, Rachel Jordan, Alice Sitch, Peymane Adab, Frits Franssen, Frank De Vries

    Loss of body mass index (BMI) is considered a feature of COPD, but in the general population cigarette smoking also leads to BMI loss. Therefore, loss of BMI may be due to the effects of COPD itself or its most common risk factor. Does smoking or COPD primarily influence BMI trajectories and is the latter part of the causal pathway to mortality? 2,223 prevalent and incident COPD and non-COPD patients with ≥3 BMI measurements from 10 practices in The Health Improvement Network (2005-2019) were grouped into never (NS), former (FS), sustained quitters (SQ), intermittent smokers (IS), and continuous smokers (CS) (ie 10 Subgroups). We modeled BMI measurements over time in each Subgroup using linear mixed effect models. Cox regression showed the association between Subgroup and mortality and BMI over time was investigated for mediation. Regardless of COPD status, FS had the highest baseline BMI(≈29.5kg/m^2), followed by NS. Both had a similar decline in BMI(≈-0.12kg/m^2/yr). The other Subgroups showed a lower baseline BMI(26-27kg/m^2). COPD and non-COPD SQ showed increasing trajectories. COPD CS had a 2x steeper decline in BMI(≈-0.30kg/m^2/yr) than non-COPD CS. Non-COPD and COPD FS (HR= 1.5 & 2.0), CS (HR=2.6 & 2.4), and COPD SQ (HR=3.0) had significant associations with mortality compared to non-COPD NS but time-varying BMI was not a significant mediator (P=0.833). Although not a prognostic mediator, BMI loss may not be a general feature of COPD but smoking as well.

  • Open Access

    Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: whole population cohort study in 46 million adults in England

    by William N Whiteley, Samantha Ip, Jennifer A Cooper, Thomas Bolton, Spencer Keene, Venexia Walker, Rachel Denholm, Ashley Akbari, Efosa Omigie, Sam Hollings, et al.

    Background: Thromboses in unusual locations after the COVID-19 vaccine ChAdOx1-S have been reported. Better understanding of population-level thrombotic risks after COVID-19 vaccination is needed. Methods: We analysed linked electronic health records from adults living in England, from 8 th December 2020 to 18 th March 2021. We estimated incidence rates and hazard ratios (HRs) for major arterial, venous and thrombocytopenic outcomes 1-28 and >28 days after first vaccination dose for ChAdOx1-S and BNT162b2 vaccines. Analyses were performed separately for ages <70 and ≥70 years, and adjusted for age, sex, comorbidities, and social and demographic factors. Results: Of 46,162,942 adults, 21,193,814 (46%) had their first vaccination during follow-up. Adjusted HRs 1-28 days after ChAdOx1-S, compared with unvaccinated rates, at ages <70 and ≥70 respectively, were 0.97 (95% CI: 0.90-1.05) and 0.58 (0.53–0.63) for venous thromboses, and 0.90 (0.86-0.95) and 0.76 (0.73-0.79) for arterial thromboses. Corresponding HRs for BNT162b2 were 0.81 (0.74–0.88) and 0.57 (0.53–0.62) for venous thromboses, and 0.94 (0.90-0.99) and 0.72 (0.70-0.75) for arterial thromboses. HRs for thrombotic events were higher at younger ages for venous thromboses after ChAdOx1-S, and for arterial thromboses after both vaccines. Rates of intracranial venous thrombosis (ICVT) and thrombocytopenia in adults aged <70 years were higher 1-28 days after ChAdOx1-S (adjusted HRs 2.27, 95% CI:1.33– 3.88 and 1.71, 1.35–2.16 respectively), but not after BNT162b2 (0.59, 0.24–1.45 and 1.00, 0.75–1.34) compared with unvaccinated. The corresponding absolute excess risks of ICVT 1-28 days after ChAdOx1-S were 0.9–3 per million, varying by age and sex. Conclusions: Increases in ICVT and thrombocytopenia after ChAdOx1-S vaccination in adults aged <70 years were small compared with its effect in reducing COVID-19 morbidity and mortality, although more precise estimates for adults <40 years are needed. For people aged ≥70 years, rates of arterial or venous thrombotic, events were generally lower after either vaccine.


  • External validation of two prognostic scores predicting exacerbations in ECLIPSE COPD patients

    by Spencer Keene, Rachel Jordan, Frank De Vries, Alice Sitch, Peymane Adab, Frits Franssen

    The BLISS and Berten’s prognostic scores are the only models developed using best-practice methodology to predict COPD exacerbations. However, they require testing in settings outside of primary care to confirm transportability. To validate the BLISS and Berten’s scores in the ECLIPSE COPD cohort. We validated both scores for predicting 2-year exacerbation with 1-year and 3-year exacerbation as secondary endpoints. Area-under-the-curve (AUC), calibration slope, and intercept/calibration-in-the-large (CITL) determined discrimination, under-or-over-prediction of risk in certain individuals or subgroups, and systematic under-or-over-prediction of risk, respectively. Of 1,749 included patients (64.8% male, mean age = 63 years, mean FEV1 = 49% of predicted), 1214 (69%) had >1 exacerbation within 2-years. The BLISS score had good discrimination (AUC= 0.73; 95% CI: 0.71-0.76) and performance remained stable at 1- and 3-years (AUC= 0.72 and 0.74, respectively). Calibration slopes improved across time periods (year 1=0.87, year 2=0.92, and year 3=0.97). Berten’s score was less accurate at 2-years (AUC= 0.70; 95% CI: 0.67 to 0.73) and at 1- and 3-years (AUC= 0.70 and 0.71, respectively). Calibration slopes for Berten9s score also improved with increasing time periods (year 1=0.81, year 2=0.84, and year 3=0.97). Berten’s score showed systematic under-prediction of risk (2-year CITL = 1.36) but the BLISS score showed worse systematic under-prediction (2-year CITL = 2.30). Both scores showed accurate discrimination. However, they exhibited systematic under-prediction of risk, especially the BLISS score. Therefore, both scores may need their intercepts updated to be valid in more severe COPD populations.